SubsidieMeestersAcceleration of the world’s first autotaxin inhibitor for the treatment of pancreatic cancer (PDAC)
iOnctura aims to accelerate clinical trials for IOA-289, a novel autotaxin inhibitor targeting pancreatic cancer, to improve treatment outcomes and attract further investment.
Projectdetails
Introduction
iOnctura is a clinical stage biopharmaceutical company dedicated to delivering innovative cancer treatments to patients with unmet medical needs.
Unique Pipeline
iOnctura's unique pipeline of drugs unlock mechanisms at the tumour-stroma-immune (T-S-I) interface, a multi-cell network that is responsible for driving tumour growth and survival as well as treatment resistance.
Pancreatic Cancer
Pancreatic cancer is one of the most lethal cancers, associated with a devastating impact on the quality of life of patients. Current treatments are largely ineffective, and there is a need for game-changing therapies.
IOA-289
IOA-289 is a first-in-class autotaxin (ATX) inhibitor that tackles cancer growth and spread by affecting core mechanisms at the T-S-I interface.
Funding and Development
The EIC Accelerator funding for CURE-PDAC will allow iOnctura to:
- Accelerate the clinical development of IOA-289 as a treatment for pancreatic cancer through Phase I/II clinical trials.
- Reach a major value inflection point.
- Attract further financial investment into the company.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 5.906.503 |
Tijdlijn
| Startdatum | 1-10-2022 |
| Einddatum | 31-3-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- IONCTURA BVpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPYMYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes. | EIC Accelerator | € 2.494.504 | 2023 | Details |
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer careNectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology. | EIC Accelerator | € 2.499.998 | 2024 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).ATXA Therapeutics aims to advance NTP42, a novel drug for pulmonary arterial hypertension, through Phase II trials and licensing to accelerate market entry and diversify its drug portfolio. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY
MYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes.
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care
Nectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology.
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
PAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH).
ATXA Therapeutics aims to advance NTP42, a novel drug for pulmonary arterial hypertension, through Phase II trials and licensing to accelerate market entry and diversify its drug portfolio.
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkankerDe ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren. | Mkb-innovati... | € 20.000 | 2020 | Details |
Targeting bicarbonate transport as a “first-in-class” therapeutic strategy to promote CD8+ T cell fitness and enhance cancer immunotherapyThis project aims to develop and commercialize bicarbonate transporter blockers to enhance CD8+ T cell efficacy and improve immunotherapy outcomes in pancreatic cancer. | ERC Proof of... | € 150.000 | 2022 | Details |
Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal AdenocarcinomaPROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity. | ERC Consolid... | € 1.999.401 | 2023 | Details |
Curing ovarian cancer through autoantibody-based therapyThis project aims to develop a novel MUC16-specific antibody drug conjugate (2B5-ADC) for ovarian cancer therapy, enhancing efficacy and targeting while preparing for phase 1 clinical trials. | ERC Proof of... | € 150.000 | 2024 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
Patiënt specifieke immunotherapie voor de behandeling van alvleesklierkanker
De ontwikkeling van een gepersonaliseerde immunotherapie voor alvleesklierkanker om de overlevingskansen van patiënten te verbeteren.
Targeting bicarbonate transport as a “first-in-class” therapeutic strategy to promote CD8+ T cell fitness and enhance cancer immunotherapy
This project aims to develop and commercialize bicarbonate transporter blockers to enhance CD8+ T cell efficacy and improve immunotherapy outcomes in pancreatic cancer.
Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal Adenocarcinoma
PROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity.
Curing ovarian cancer through autoantibody-based therapy
This project aims to develop a novel MUC16-specific antibody drug conjugate (2B5-ADC) for ovarian cancer therapy, enhancing efficacy and targeting while preparing for phase 1 clinical trials.
RESTORING IMMUNITY CONTROL OF GI CANCERS
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.